Gossamer Bio (GOSS) Doubled in Two Sessions. Its Own Loan Documents Leave About $17 Million of Room Before a Covenant Breaks.
GOSS ran 97% in two sessions on an FDA update that says the agency will read a failed Phase 3, not approve it. The June 4 indenture tells a harder story: a $40 million liquidity covenant tested monthly against $57 million of cash, and a share count authorized to reach four billion.
Gossamer Bio ($GOSS) closed Friday at $0.136. On Monday it closed at $0.199, a 46% move on 320.3 million shares, against a recent daily average closer to 12 million. In Tuesday's pre-market it was trading near $0.268. Two sessions, a near-double, and roughly 65% of the entire share count changing hands in one of them.
The catalyst was a press release issued Monday morning. Gossamer announced that after a Pre-NDA Type B meeting with the FDA in mid-June, it will submit a New Drug Application for seralutinib in pulmonary arterial hypertension in September 2026. It also announced it had reacquired worldwide rights to the drug from Chiesi Farmaceutici, its Italian partner. The stream read both items as validation.
Neither one is quite what the market seems to think it is. And neither one is the most important number Gossamer disclosed on Monday.
What the FDA actually said
The operative sentence in the 8-K is precise, and it is worth reading slowly:
"Based on the meeting minutes, the FDA characterized the degree of statistical significance and the magnitude of the treatment effect observed in PROSERA as review issues rather than filing issues."
A filing issue is a reason the agency refuses to accept your application. A review issue is a reason it might reject the drug after reading it. What the FDA told Gossamer is that it will not turn the paperwork away at the door. Not that the paperwork wins. Gossamer's own filing says so in the next breath: "the FDA's ultimate determination on approvability will be made upon review of the complete NDA."
That distinction carries weight here because of what PROSERA actually showed.
The trial missed
PROSERA randomized 390 patients, 197 to seralutinib and 193 to placebo. The primary endpoint was change in six-minute walk distance at Week 24. Seralutinib delivered a placebo-adjusted improvement of +13.3 meters, with a p-value of 0.0320 against a prespecified alpha threshold of 0.025.
It missed. Not by much, but the threshold was set in advance and the result landed on the wrong side of it.
The supporting picture is more mixed than the headline suggests. In the prespecified intermediate-and-high-risk subgroup (n=234), the placebo-adjusted gain was +20.0 meters (p=0.0207). NT-proBNP, a cardiac stress biomarker, improved by a location shift of -120.4 ng/L (p=0.0002). All four key secondary endpoints favored the drug. On safety, treatment-emergent adverse events ran 86.5% versus 80.5% for placebo and serious adverse events 16.0% versus 18.9%. But transaminase elevations at three times the upper limit of normal or higher hit 13% of seralutinib patients versus 1% on placebo.
So: a drug with real biological activity, a signal that concentrates in sicker patients, a liver-enzyme finding a reviewer will not ignore, and a pivotal trial that did not clear its own bar. Gossamer will file on one adequate and well-controlled study plus confirmatory evidence from the Phase 2 TORREY trial. That is a legitimate regulatory path. It is also a harder one than a clean win, and it lands in front of a division that has just watched Merck's Winrevair build a $1.4 billion franchise in its first full year on the market with unambiguous data behind it.
Read the Chiesi handback correctly
In May 2024, Chiesi agreed to pay Gossamer $160 million in development reimbursement, plus up to $146 million in regulatory and $180 million in sales milestones, in exchange for ex-US rights and a 50/50 split of US commercial profits and losses. Gossamer had collected $48.6 million of that reimbursement by the end of Q1 2026.
On July 23, the agreement was terminated. Chiesi returned the rights and paid Gossamer $5 million to close out development costs. In exchange, Gossamer now owes Chiesi success-based milestones and a capped royalty on net sales. Seralutinib is also in-licensed from Pulmokine, which carries its own tiered royalty in the mid-to-high single digits plus up to $48 million in development milestones and $190 million in sales milestones.
Framed as "reacquisition of worldwide rights," that reads like a company taking back its crown jewel. Framed by what it does to the income statement, it reads differently. The partner with full access to the PROSERA dataset declined to fund a launch, a 50/50 cost share became a 100% Gossamer obligation, and the drug now carries two royalty stacks instead of one.
Which brings us to the number that actually governs this stock over the next sixty days. It is not in the press release. It is in the indenture Gossamer signed on June 4.
The rest of this briefing is for paid members: the minimum-liquidity covenant that now tests monthly and how much room the company's own cash figure leaves against it, the full share-count stack from 489 million to 1.16 billion, the springing maturity date that turns a 2030 obligation into a March 2027 one, the Nasdaq deadline that would trigger a $65 million cash repurchase Gossamer cannot fund, and a scenario-by-scenario map of the price zones.
AlphaBriefing Paid gets you every investment thesis, scenario framework, and catalyst brief we publish, the analysis private intel clients pay four figures for, at a fraction of that.